The United States Lung Cancer Treatment Market is expected to reach $15.86 billion by 2032, with the Targeted Therapy segment holding 50.5% market share. North America leads 37% of the global market

The global lung cancer treatment market size reached US$ 32.64 billion in 2024 and is expected to reach US$ 73.29 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/lung-cancer-treatment-market?pratik

The Lung Cancer Treatment Market is growing due to rising lung cancer prevalence, increasing adoption of targeted therapies and immunotherapies, advanced diagnostic technologies, government initiatives for cancer awareness, and growing healthcare infrastructure globally, driving demand for effective and personalized treatment options.

United States industry development
✅U.S. lung cancer treatment market size was estimated at $9.51 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.65% to reach $15.86 billion by 2032

✅ November 2025: Amgen received full FDA approval for IMDELLTRA, a treatment for extensive-stage small cell lung cancer, reinforcing its status as a standard of care and highlighting ongoing investment in advanced lung cancer therapies in the US.

✅ 2025 (general funding): The Lung Cancer Research Foundation (LCRF) announced its 2025 Leading Edge Research Grant Program focusing on lung cancer treatment innovations, including grants aimed at overcoming resistance to lung cancer therapies through cutting-edge research projects.

✅ October 2025: American Lung Association committed US$ 22 million to new research grants and clinical projects aimed at improving lung disease and lung cancer treatment and prevention.

✅ March 2025: Nuvation Bio secured US$ 250 million financing to support the launch and further development of its lung cancer drug candidate, taletrectinib.

Global industry development

✅ 2025: Oxford Cancer Analytics (OXcan), a medtech company developing early cancer detection tests using AI and advanced proteomics, raised $11 million in Series A funding from global institutional investors focused on disease detection and diagnostics, indicating significant funding interest in lung cancer diagnostics and treatment technologies.

✅ May 2025: Pfizer signed a global licensing deal with China's 3SBio Inc. for lung‐cancer drug candidate SSGJ‐707 paying US$ 1.25 billion upfront plus up to US$ 4.8 billion in milestones.

✅ July 2025: Nanobiotix expanded its lung‐cancer treatment pipeline (NBTXR3) and confirmed financial backing that extends its cash runway into mid‐2026, securing stability for ongoing global trials.

Recent Merges & acquisition
→ Genmab acquired Merus for $8 billion in Q3 2025, adding a portfolio of approved and late-stage assets targeting adenocarcinoma, non-small cell lung cancer, head and neck, and colorectal cancers.

→ HistoSonics was acquired for $2.3 billion in Q3 2025, expanding its focused ultrasound therapy portfolio into solid tumors including lung cancer.

→ Sino Biopharmaceutical acquired LaNova Medicines covering Phase I-III and preclinical oncology assets, including therapies for non-small cell lung cancer, in a Q3 2025 deal valued at $951 million.

Market Segmentation-

Segmentation by Treatment Type:
→ Targeted Therapy: This segment is expected to dominate the lung cancer treatment market with about 50.5% market share in 2025. Targeted therapies focus on specific genetic mutations in lung cancer, offering improved patient outcomes and fewer side effects compared to traditional chemotherapy.

→ Chemotherapy: Chemotherapy remains crucial, especially for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) stages IIIA and IIIB. It holds a significant share but is lesser than targeted therapy.

→ Immunotherapy: Immunotherapy is the fastest-growing segment driven by its durable response in varied lung cancer subtypes and stages, holding a smaller but rapidly expanding share.

→ Radiation Therapy: This includes external beam radiation therapy (EBRT) and brachytherapy, contributing a moderate share as complementary or palliative options.

→ Surgical Procedures: Includes lobectomy, pneumonectomy, and segmentectomy, mainly used in operable cases with a smaller market share compared to drug therapies.

Segmentation by Cancer Type:
→ Non-Small Cell Lung Cancer (NSCLC): The dominant cancer type segment, accounting for approximately 83-85% of the market share due to its high prevalence and the availability of targeted and immunotherapies.

→ Small Cell Lung Cancer (SCLC): Represents the remaining market share, characterized by aggressive disease and more limited treatment options.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=lung-cancer-treatment-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

Regional insights:-

→ North America holds a leading market share around 37%, driven by strong healthcare infrastructure, high adoption of advanced therapies, significant R&D investment, and favorable reimbursement policies.

→ Asia Pacific is the fastest-growing region with a market share estimated around 24.5%, with high growth fueled by rising healthcare expenditure, urbanization, increasing lung cancer prevalence, and improving healthcare access especially in countries like China and India.

→ Europe, Latin America, and the Middle East & Africa hold smaller shares compared to North America and Asia Pacific, but growth in these regions is supported by increasing healthcare investments and expanding treatment adoption.

Key Players
Merck & Co., Inc., Pfizer Inc., AstraZeneca, Amgen Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceuticals U.S.A., Inc., Amneal Pharmaceuticals LLC., Genentech USA, Inc., Rigel Pharmaceuticals, Inc., Daiichi Sankyo, Inc. and among others.

→ Merck & Co., Inc. is a leader known for its immunotherapy drug KEYTRUDA, which is a major therapy for advanced non-small cell lung cancer (NSCLC). Merck focuses heavily on therapeutic innovation and collaborations to sustain its competitive edge in lung cancer treatment. It is one of the largest contributors to the immunotherapy segment of the market.​

→ Bristol-Myers Squibb Company is another key player with its immunotherapy product OPDIVO, which is widely used for various lung cancer types including NSCLC. Bristol-Myers Squibb holds a significant market share because of its comprehensive treatment portfolio and active R&D pipeline in immuno-oncology.​

→ AstraZeneca is prominent for its targeted therapy TAGRISSO, which treats EGFR mutation-positive lung cancer patients. AstraZeneca emphasizes precision medicine and biomarker-based therapy options, capturing large market shares in the targeted treatment segment.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/lung-cancer-treatment-market?pratik

Market Drivers:-
→ Key drivers of the Lung Cancer Treatment Market include the rising global prevalence of lung cancer, advances in immunotherapy and targeted therapies, increased research and development investments by pharmaceutical companies, supportive governmental policies for oncology, and growing patient awareness. Technological innovations, especially in combination therapies, are enhancing treatment efficacy and patient outcomes, propelling market growth significantly.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.